EPIRUS Biopharmaceuticals Receives $36,000,000 Series B Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d33b9e8c-69d1-430c-b91c-c9fe39543c2f
Date
4/17/2014
Company Name
EPIRUS Biopharmaceuticals
Mailing Address
699 Boylston Street 11th Floor Boston, MA 02199 USA
Company Description
The biopharmacuticals industry is approaching an unprecedented biologics patent cliff, with emerging markets forging their own regulatory landscapes. EPIRUS is seizing the opportunity with a new business model that adapts to the changing dynamics and regulations of today’s market conditions.
Website
http://www.epirusbiopharma.com
Transaction Type
Venture Equity
Transaction Amount
$36,000,000
Transaction Round
Series B
Proceeds Purposes
Through this transaction, we gain access to additional financial resources as well as clinical trial experience in the rheumatoid arthritis space. Our combined team is committed to expanding patient access to important medications.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor